Biotech IPOs Rebound...But Where's BioRx?
Executive Summary
1995 has witnessed a startling turnaround in the biotech public equity market, but while biotech IPOs haven’t reached these levels since the financing window of 1991-92, they don’t look like they used to. As the chart below illustrates, today’s biotech IPO investor tends to favor biodiagnostic companies and companies selling drug development services.